Clinical trial
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007…
NCT00394251 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00394251 |
|---|---|
| Title | Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer |
| Official title | An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Adriamycin and Cytoxan (AC), ABI-007, Taxol, Bevacizumab, pegfilgrastim |
| Enrollment | 197 |
| Start date | Aug 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Oct 31, 2006 |
| Last update posted | Nov 25, 2019 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: